Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLC011
MIFTS: 56

Pilocytic Astrocytoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pilocytic Astrocytoma

About this section

MalaCards integrated aliases for Pilocytic Astrocytoma:

Name: Pilocytic Astrocytoma 54 60 30 56 6 74
Juvenile Pilocytic Astrocytoma 54 74

Characteristics:

Orphanet epidemiological data:

60
pilocytic astrocytoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 35 C71.9
UMLS via Orphanet 75 C0334583
Orphanet 60 ORPHA251612
Sources

Summaries for Pilocytic Astrocytoma

About this section
NIH Rare Diseases : 54 Pilocytic astrocytoma is an often benign, slow-growing tumor of the brain or spinal cord. The tumor may be in the form of a cyst and usually does not spread to nearby tissues. Symptoms vary depending upon the size and location of the tumor. Most symptoms result from increased pressure on the brain and include headaches, nausea, vomiting, balance problems, and vision abnormalities. The underlying cause of a pilocytic astrocytoma is unknown. It most commonly occurs in children and young adults, and in people with neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome, and tuberous sclerosis. This type of tumor can often be cured with surgery.

MalaCards based summary : Pilocytic Astrocytoma, also known as juvenile pilocytic astrocytoma, is related to pilocytic astrocytoma of cerebellum and juvenile pilocytic astrocytoma, and has symptoms including headache An important gene associated with Pilocytic Astrocytoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Lomustine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and cerebellum, and related phenotypes are Decreased viability in esophageal squamous lineage and behavior/neurological

Wikipedia : 77 Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its... more...

Sources

Related Diseases for Pilocytic Astrocytoma

About this section

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 pilocytic astrocytoma of cerebellum 34.0 BRAF IDH1 KIAA1549 NF1
2 juvenile pilocytic astrocytoma 33.3 CDKN2A GFAP NF1 TIMP3 TP53
3 encephalocraniocutaneous lipomatosis 30.8 FGFR1 KRAS
4 dysembryoplastic neuroepithelial tumor 30.7 GFAP IDH1
5 ganglioglioma 30.6 BRAF GFAP TP53
6 glioma susceptibility 1 30.4 GFAP IDH1 TP53
7 meningioma, familial 30.2 CDKN2A GFAP NF1 TP53
8 obstructive hydrocephalus 30.2 GFAP NF1
9 glioblastoma 30.2 BRAF CDKN2A FGFR1 IDH1 NF1 TP53
10 glioblastoma multiforme 30.1 CDKN2A GFAP IDH1 TP53
11 gliofibroma 30.1 GFAP NF1 TP53
12 neurilemmoma 30.1 GFAP NF1 SOX10
13 pilomyxoid astrocytoma 30.1 BRAF FGFR1 GFAP KIAA1549 KRAS NF1
14 pleomorphic xanthoastrocytoma 30.0 BRAF GFAP IDH1 TP53
15 glioma 30.0 BRAF CDKN2A FGFR1 IDH1 NF1 TP53
16 medulloblastoma 30.0 FGFR1 GFAP IDH1 TIMP3 TP53
17 adenocarcinoma 29.8 BRAF CDKN2A FGFR1 KRAS TP53
18 fibrillary astrocytoma 29.8 GFAP IDH1 KIAA1549 TP53
19 gliosarcoma 29.8 FGFR1 GFAP IDH1 TP53
20 oligodendroglioma 29.6 CDKN2A GFAP IDH1 SOX10 TP53
21 grade iii astrocytoma 29.6 APOD CDKN2A GFAP TP53
22 childhood pilocytic astrocytoma 12.6
23 astrocytoma 11.3
24 neurofibromatosis, type i 10.5
25 neurofibromatosis, type iv, of riccardi 10.5
26 histiocytic sarcoma 10.4 BRAF CDKN2A
27 nevus of ota 10.4 BRAF TP53
28 rare adenocarcinoma of the breast 10.3 KRAS TP53
29 acral lentiginous melanoma 10.3 BRAF CDKN2A
30 mutyh-associated polyposis 10.3 KRAS TP53
31 spinal meningioma 10.3
32 secretory meningioma 10.3
33 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
34 conventional leiomyosarcoma 10.3 CDKN2A NF1
35 intracranial chondrosarcoma 10.3 IDH1 TP53
36 bladder carcinoma in situ 10.3 CDKN2A TP53
37 vulva squamous cell carcinoma 10.3 CDKN2A TP53
38 urachal adenocarcinoma 10.3 BRAF KRAS NF1
39 rhabdoid meningioma 10.3 BRAF GFAP
40 scrotal carcinoma 10.3 CDKN2A TP53
41 colonic benign neoplasm 10.3 BRAF KRAS
42 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
43 pulmonic stenosis 10.2 BRAF KRAS NF1
44 syringocystadenoma papilliferum 10.2 GFAP KRAS
45 thyroid lymphoma 10.2 CDKN2A TP53
46 vulvar disease 10.2 CDKN2A TP53
47 hyperplastic polyposis syndrome 10.2 BRAF KRAS TP53
48 lymphoepithelioma-like thymic carcinoma 10.2 CDKN2A IDH1
49 mature teratoma 10.2 BRAF KRAS TP53
50 bartholin's gland disease 10.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Pilocytic Astrocytoma:



Diseases related to Pilocytic Astrocytoma
Sources

Symptoms & Phenotypes for Pilocytic Astrocytoma

About this section

UMLS symptoms related to Pilocytic Astrocytoma:


headache

GenomeRNAi Phenotypes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 APOD BRAF CDKN2A GFAP IDH1 KIAA1549

MGI Mouse Phenotypes related to Pilocytic Astrocytoma:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 APOD BRAF CDKN2A FGFR1 GFAP KIAA1549
2 homeostasis/metabolism MP:0005376 10.39 APOD BRAF CDKN2A FGFR1 GFAP IDH1
3 growth/size/body region MP:0005378 10.32 BRAF CDKN2A FGFR1 GFAP IDH1 KRAS
4 cellular MP:0005384 10.3 BRAF CDKN2A FGFR1 GFAP KRAS NF1
5 mortality/aging MP:0010768 10.29 APOD BRAF CDKN2A FGFR1 GFAP IDH1
6 immune system MP:0005387 10.28 BRAF CDKN2A FGFR1 GFAP IDH1 KIAA1549
7 cardiovascular system MP:0005385 10.26 APOD BRAF CDKN2A FGFR1 GFAP KRAS
8 hematopoietic system MP:0005397 10.21 BRAF CDKN2A FGFR1 IDH1 KRAS NF1
9 digestive/alimentary MP:0005381 10.2 BRAF CDKN2A FGFR1 GFAP KRAS NF1
10 endocrine/exocrine gland MP:0005379 10.19 BRAF CDKN2A FGFR1 KRAS NF1 SOX10
11 integument MP:0010771 10.18 BRAF CDKN2A FGFR1 KRAS NF1 SOX10
12 embryo MP:0005380 10.14 BRAF CDKN2A FGFR1 KRAS NF1 SOX10
13 nervous system MP:0003631 10.1 APOD BRAF CDKN2A FGFR1 GFAP KRAS
14 muscle MP:0005369 10.06 BRAF CDKN2A FGFR1 GFAP KRAS NF1
15 hearing/vestibular/ear MP:0005377 10.04 APOD BRAF FGFR1 KRAS NF1 TP53
16 liver/biliary system MP:0005370 10.04 BRAF CDKN2A KRAS NF1 SQSTM1 TIMP3
17 limbs/digits/tail MP:0005371 9.99 BRAF FGFR1 KRAS NF1 SOX10 TP53
18 neoplasm MP:0002006 9.91 BRAF CDKN2A KRAS NF1 SOX10 TP53
19 normal MP:0002873 9.91 BRAF FGFR1 GFAP KRAS NF1 SOX10
20 pigmentation MP:0001186 9.87 BRAF CDKN2A KRAS NF1 SOX10 TIMP3
21 respiratory system MP:0005388 9.76 BRAF CDKN2A IDH1 KRAS NF1 SOX10
22 renal/urinary system MP:0005367 9.73 BRAF FGFR1 KRAS NF1 TIMP3 TP53
23 skeleton MP:0005390 9.56 BRAF CDKN2A FGFR1 IDH1 KRAS NF1
24 vision/eye MP:0005391 9.23 BRAF CDKN2A FGFR1 GFAP KRAS NF1
Sources

Drugs & Therapeutics for Pilocytic Astrocytoma

About this section

Drugs for Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
2
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
3
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 2068-78-2, 57-22-7 5978
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
6
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
7
Histamine Approved, Investigational Phase 3 51-45-6 774
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Alkylating Agents Phase 2, Phase 3,Phase 1
12 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
13 Dermatologic Agents Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 2, Phase 3,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
16 Narcotics Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Analgesics Phase 3
19 Anesthetics, Intravenous Phase 3
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Anesthetics, General Phase 3
22 Anesthetics Phase 3
23 Analgesics, Opioid Phase 3
24 Central Nervous System Depressants Phase 3
25 Peripheral Nervous System Agents Phase 3
26 Cola Phase 3,Phase 1
27 Cholinesterase Inhibitors Phase 3,Phase 2
28 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
29 Nootropic Agents Phase 3,Phase 2
30 Cholinergic Agents Phase 3,Phase 2
31 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
32 Central Nervous System Stimulants Phase 3,Phase 2
33 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
34 Histamine Antagonists Phase 3
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Anti-Allergic Agents Phase 3
38 Antipruritics Phase 3
39 Histamine H1 Antagonists Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Dexmethylphenidate Hydrochloride Phase 3
42 Dopamine Uptake Inhibitors Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
47
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 5284616 6436030
48
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 70789204 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
50
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
6 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
7 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
8 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
9 Bevacizumab in Recurrent Grade II and III Glioma Completed NCT01164189 Phase 2 Temozolomide
10 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
11 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
12 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
13 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
14 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
15 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
16 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
17 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
18 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
19 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
20 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
21 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
22 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
24 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
25 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
26 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
27 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
28 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
29 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
32 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
33 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
34 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
35 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
36 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
37 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Completed NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
38 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
39 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
40 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
41 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
42 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
43 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
44 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
45 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
46 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
47 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
48 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
49 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
50 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1

Search NIH Clinical Center for Pilocytic Astrocytoma

Sources

Genetic Tests for Pilocytic Astrocytoma

About this section

Genetic tests related to Pilocytic Astrocytoma:

# Genetic test Affiliating Genes
1 Pilocytic Astrocytoma 30
Sources

Anatomical Context for Pilocytic Astrocytoma

About this section

MalaCards organs/tissues related to Pilocytic Astrocytoma:

42
Brain, Spinal Cord, Cerebellum, Bone, Thyroid, Pineal, Colon
Sources

Publications for Pilocytic Astrocytoma

About this section

Articles related to Pilocytic Astrocytoma:

(show top 50) (show all 439)
# Title Authors Year
1
Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. ( 30953904 )
2019
2
Twenty-three years follow-up after low-dose Gamma Knife surgery of a brainstem juvenile pilocytic astrocytoma: a case report and review of the literature. ( 30997566 )
2019
3
Hypertrophic olivary degeneration in a 16-year-old girl after subtotal surgery of a brainstem pilocytic astrocytoma - a case report. ( 31019597 )
2019
4
Comparison of conventional, diffusion, and perfusion MRI between infratentorial ganglioglioma and pilocytic astrocytoma. ( 31032625 )
2019
5
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series. ( 31045718 )
2019
6
Multifocal Infra-Tentorial Pilocytic Astrocytoma in an Adult Patient: A Case Report. ( 31082554 )
2019
7
Primary spinal pilocytic astrocytoma: clinical study with long-term follow-up in 16 patients and a literature review. ( 31098788 )
2019
8
Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. ( 30192422 )
2019
9
Endoscopic transnasal resection of optic pathway pilocytic astrocytoma. ( 30338361 )
2019
10
Solid non-enhancing cerebellar pilocytic astrocytoma case report. ( 30366781 )
2019
11
ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. ( 30499772 )
2019
12
Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. ( 30575814 )
2019
13
MR imaging features of spinal pilocytic astrocytoma. ( 30642288 )
2019
14
Extent of resection predicts risk of progression in adult pilocytic astrocytoma. ( 30653383 )
2019
15
Surgical Management and Outcome of a Bilateral Thalamic Pilocytic Astrocytoma: Case Report and Review of the Literature. ( 30677772 )
2019
16
Hemorrhagic presentation of frontal partially calcified pilocytic astrocytoma in an 18-year-old woman: A case report and literature review as "clinical case". ( 30711258 )
2019
17
The benefit of surveillance imaging for paediatric cerebellar pilocytic astrocytoma. ( 30770993 )
2019
18
Unusual KRAS missense mutation (p.E63K) in patient with juvenile pilocytic astrocytoma of the tectum. ( 30798277 )
2019
19
Holocord Pilocytic Astrocytoma in an Adult: A Rare Case Report and Review of the Literature. ( 30902768 )
2019
20
CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. ( 29804288 )
2019
21
Rare compound heterozygous variants in PNKP identified by whole exome sequencing in a German patient with ataxia-oculomotor apraxia 4 and pilocytic astrocytoma. ( 29498415 )
2018
22
Editors' note: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807919 )
2018
23
Reader response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807920 )
2018
24
Author response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807921 )
2018
25
An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. ( 29851180 )
2018
26
Circulating serum oncologic miRNA in pediatric juvenile pilocytic astrocytoma patients predicts mural nodule volume. ( 29911246 )
2018
27
Pilocytic Astrocytoma with Adipocytic Differentiation: A Rare Histological Variation. ( 30090152 )
2018
28
An elderly patient presenting with a primary spinal multifocal intradural extramedullary pilocytic astrocytoma: a case report and review of the literature. ( 30092761 )
2018
29
Multilineage ACTB mutation in a patient with fibro-osseous maxillary lesion and pilocytic astrocytoma. ( 30152002 )
2018
30
Use of Apparent Diffusion Coefficient Histogram in Differentiating Between Medulloblastoma and Pilocytic Astrocytoma in Children. ( 30173245 )
2018
31
Clinical Significance of T2*gradient-recalled Echo/susceptibility-weighted Imaging Sequences in Evaluating Superficial Siderosis in the Setting of Intracerebral Tumors: Pilocytic Astrocytoma. ( 30197827 )
2018
32
Leptomeningeal dissemination of spinal pilocytic astrocytoma: a rare entity. ( 30269096 )
2018
33
"Integrated diagnosis" of pilocytic astrocytoma: Molecular diagnostic procedure for an unusual case. ( 30417961 )
2018
34
Differentiation between pilocytic astrocytoma and glioblastoma: a decision tree model using contrast-enhanced magnetic resonance imaging-derived quantitative radiomic features. ( 30421019 )
2018
35
Proliferative Index in Pediatric Pilocytic Astrocytoma by Region of Origin and Prediction of Clinical Behavior. ( 30428478 )
2018
36
Pilocytic Astrocytoma with Gangliocytic Differentiation to Pilomyxoid Astrocytoma-expanding the Morphological Spectrum: Case Report and Literature Review. ( 30459892 )
2018
37
Mathematical skills in children with pilocytic astrocytoma. ( 30523458 )
2018
38
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. ( 30530705 )
2018
39
Intraventricular Pilocytic Astrocytoma With KIAA1549/BRAF Fusion Arising in a 44-Year Old. ( 30561708 )
2018
40
Rebleeding after 18 years of a haemorrhagic pilocytic astrocytoma: prognostic implications of conservative management. Case report and literature review. ( 30579034 )
2018
41
Unedited microneurosurgery of a posterior fossa pilocytic astrocytoma. ( 30595956 )
2018
42
Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. ( 28960151 )
2018
43
Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. ( 28968151 )
2018
44
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
45
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
46
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
47
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
48
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
49
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
50
Management and Survival of Adult Patients with Pilocytic Astrocytoma in the National Cancer Database. ( 29427814 )
2018
Sources

Variations for Pilocytic Astrocytoma

About this section

ClinVar genetic disease variations for Pilocytic Astrocytoma:

6 (show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.1240C> T (p.Arg414Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs137854567 GRCh37 Chromosome 5, 112154969: 112154969
2 APC NM_000038.5(APC): c.1240C> T (p.Arg414Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs137854567 GRCh38 Chromosome 5, 112819272: 112819272
3 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
4 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348
5 RET NM_020975.4(RET): c.1344C> G (p.Asn448Lys) single nucleotide variant Uncertain significance rs549907428 GRCh37 Chromosome 10, 43606735: 43606735
6 RET NM_020975.4(RET): c.1344C> G (p.Asn448Lys) single nucleotide variant Uncertain significance rs549907428 GRCh38 Chromosome 10, 43111287: 43111287
7 SDHA NM_004168.3(SDHA): c.91C> T (p.Arg31Ter) single nucleotide variant Pathogenic rs142441643 GRCh37 Chromosome 5, 223624: 223624
8 SDHA NM_004168.3(SDHA): c.91C> T (p.Arg31Ter) single nucleotide variant Pathogenic rs142441643 GRCh38 Chromosome 5, 223509: 223509
9 PALB2 NM_024675.3(PALB2): c.1478C> T (p.Pro493Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs770965402 GRCh37 Chromosome 16, 23646389: 23646389
10 PALB2 NM_024675.3(PALB2): c.1478C> T (p.Pro493Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs770965402 GRCh38 Chromosome 16, 23635068: 23635068
11 MSH6 NM_000179.2(MSH6): c.188C> G (p.Ser63Cys) single nucleotide variant Uncertain significance rs587779920 GRCh37 Chromosome 2, 48010560: 48010560
12 MSH6 NM_000179.2(MSH6): c.188C> G (p.Ser63Cys) single nucleotide variant Uncertain significance rs587779920 GRCh38 Chromosome 2, 47783421: 47783421
13 RUNX1 NM_001754.4(RUNX1): c.1243C> T (p.Gln415Ter) single nucleotide variant Uncertain significance GRCh38 Chromosome 21, 34792335: 34792335
14 RUNX1 NM_001754.4(RUNX1): c.1243C> T (p.Gln415Ter) single nucleotide variant Uncertain significance GRCh37 Chromosome 21, 36164632: 36164632
15 NF1 NM_000267.3(NF1): c.6103A> T (p.Lys2035Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 17, 31336653: 31336653
16 NF1 NM_000267.3(NF1): c.6103A> T (p.Lys2035Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 17, 29663671: 29663671
17 ALK NM_004304.5(ALK): c.2633-3C> T single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 29229069: 29229069
18 ALK NM_004304.5(ALK): c.2633-3C> T single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 29451935: 29451935
19 FLCN NM_144997.7(FLCN): c.872-1G> T single nucleotide variant Likely pathogenic GRCh38 Chromosome 17, 17219210: 17219210
20 FLCN NM_144997.7(FLCN): c.872-1G> T single nucleotide variant Likely pathogenic GRCh37 Chromosome 17, 17122524: 17122524

Copy number variations for Pilocytic Astrocytoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38161 10 1 3000000 Gain DIP2C Pilocytic astrocytoma
2 40599 10 130600000 135534747 Loss DRD1IP Pilocytic astrocytoma
3 64537 12 129300000 133851895 Loss BCL7A Pilocytic astrocytoma
4 84233 14 24600000 33300000 Loss FOXG1B Pilocytic astrocytoma
5 97079 15 98500000 102531392 Loss LASS3 Pilocytic astrocytoma
6 112680 17 40811265 40819024 Loss TUBG2 Pilocytic astrocytoma
7 112684 17 40834631 40852011 Loss CNTNAP1 Pilocytic astrocytoma
8 220399 7 138200000 143100000 Amplification Pilocytic astrocytoma
9 227901 7 72200000 77500000 Loss BCL7B Pilocytic astrocytoma
10 230764 8 1 2200000 Loss Pilocytic astrocytoma
11 234563 8 136400000 146364022 Gain COL22A1 Pilocytic astrocytoma
12 234873 8 139900000 146364022 Gain CYHR1 Pilocytic astrocytoma
13 234878 8 139900000 146364022 Gain FOXH1 Pilocytic astrocytoma
14 234881 8 139900000 146364022 Gain GPT Pilocytic astrocytoma
15 234884 8 139900000 146364022 Gain KIFC2 Pilocytic astrocytoma
16 234886 8 139900000 146364022 Gain LRRC14 Pilocytic astrocytoma
17 234888 8 139900000 146364022 Gain LRRC24 Pilocytic astrocytoma
18 234890 8 139900000 146364022 Gain MFSD3 Pilocytic astrocytoma
19 234893 8 139900000 146364022 Gain PPP1R16A Pilocytic astrocytoma
20 234897 8 139900000 146364022 Gain RECQL4 Pilocytic astrocytoma
21 244900 9 1 2200000 Loss ANKRD15 Pilocytic astrocytoma
22 256191 9 9000000 28000000 Loss SH3GL2 Pilocytic astrocytoma
Sources

Expression for Pilocytic Astrocytoma

About this section
Search GEO for disease gene expression data for Pilocytic Astrocytoma.
Sources

Pathways for Pilocytic Astrocytoma

About this section

Pathways related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 65
Show member pathways
 13.65 BRAF CDKN2A FGFR1 GFAP KRAS NF1
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.22 BRAF FGFR1 KRAS NF1 SQSTM1 TP53
3
Phospholipase-C Pathway 65
Show member pathways
 12.93 BRAF FGFR1 KRAS TIMP3 TP53
4
Endometrial cancer 38
Show member pathways
 12.71 BRAF CDKN2A FGFR1 KRAS TP53
5
Pathways in cancer 38
12.68 BRAF CDKN2A FGFR1 KRAS TP53
6
Ras signaling pathway 38
Show member pathways
 12.6 BRAF FGFR1 KRAS NF1
7
MAPK signaling pathway 1 38
12.58 BRAF FGFR1 KRAS NF1 TP53
8
Gastric cancer 38
Show member pathways
 12.56 BRAF CDKN2A FGFR1 KRAS TP53
9
Glioma 38
Show member pathways
 12.39 BRAF CDKN2A FGFR1 KRAS NF1 TP53
10
MicroRNAs in cancer 38
12.38 CDKN2A KRAS TIMP3 TP53
11
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.36 BRAF FGFR1 KRAS TP53
12
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.13 FGFR1 KRAS TIMP3 TP53
13
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.09 BRAF KRAS TIMP3 TP53
14
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.06 BRAF FGFR1 KRAS TP53
15
mTOR Pathway 73
Show member pathways
 12.05 BRAF KRAS TP53
16
NGF Pathway 65
Show member pathways
 12.01 BRAF KRAS TP53
17
Cellular senescence (KEGG) 38
11.96 CDKN2A KRAS SQSTM1 TP53
18
Integrated Breast Cancer Pathway 1
11.92 BRAF KRAS NF1 TP53
19
DNA Damage Response (only ATM dependent) 1
11.87 CDKN2A KRAS TP53
20
MAP Kinase Signaling 4
11.86 BRAF KRAS NF1
21
Proteoglycans in cancer 38
11.86 BRAF FGFR1 KRAS TIMP3 TP53
22
Oncogenic MAPK signaling 67
Show member pathways
 11.84 BRAF KIAA1549 KRAS NF1
23
Neural Crest Differentiation 1
11.8 FGFR1 GFAP SOX10
24
Senescence and Autophagy in Cancer 1
11.69 BRAF CDKN2A SQSTM1 TP53
25
VEGF Pathway (Tocris) 62
Show member pathways
 11.68 BRAF FGFR1 KRAS
26
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.67 FGFR1 GFAP SOX10
27
G-protein signaling_RhoA regulation pathway 23
11.6 BRAF FGFR1 KRAS TIMP3
28
Mitophagy - animal 38
11.54 KRAS SQSTM1 TP53
29
Bladder cancer 1 38
11.42 BRAF CDKN2A KRAS TP53
30
Vemurafenib Pathway, Pharmacodynamics 62
11.29 BRAF FGFR1 KRAS
31
Central carbon metabolism in cancer 38
11.07 FGFR1 IDH1 KRAS TP53
32
Glioblastoma Multiforme 65
11.07 BRAF CDKN2A KRAS NF1 TP53
33
Inhibition of Ribosome Biogenesis by p14(ARF) 65
10.99 CDKN2A TP53
34
TP53 Network 1
Show member pathways
 10.99 CDKN2A TP53
Sources

GO Terms for Pilocytic Astrocytoma

About this section

Cellular components related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.23 BRAF CDKN2A IDH1 KRAS SDHA SOX10

Biological processes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.8 CDKN2A NF1 SQSTM1 TP53
2 negative regulation of apoptotic process GO:0043066 9.71 BRAF SOX10 SQSTM1 TP53
3 MAPK cascade GO:0000165 9.62 BRAF FGFR1 KRAS NF1
4 positive regulation of gene expression GO:0010628 9.55 BRAF CDKN2A KRAS SOX10 TP53
5 negative regulation of cell-matrix adhesion GO:0001953 9.54 CDKN2A NF1
6 cellular response to drug GO:0035690 9.54 BRAF SOX10 TP53
7 regulation of long-term neuronal synaptic plasticity GO:0048169 9.52 KRAS NF1
8 positive regulation of cellular senescence GO:2000774 9.51 CDKN2A KRAS
9 regulation of synaptic transmission, GABAergic GO:0032228 9.48 KRAS NF1
10 replicative senescence GO:0090399 9.46 CDKN2A TP53
11 negative regulation of protein import into nucleus GO:0042308 9.43 APOD NF1
12 visual learning GO:0008542 9.43 BRAF KRAS NF1
13 forebrain astrocyte development GO:0021897 8.96 KRAS NF1
14 Ras protein signal transduction GO:0007265 8.92 CDKN2A KRAS NF1 TP53

Molecular functions related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 BRAF FGFR1 GFAP IDH1 SOX10 SQSTM1
Sources

Sources for Pilocytic Astrocytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....